Physiological Basis
Penile duplex Doppler ultrasound (PDDU) is the gold-standard diagnostic investigation for erectile dysfunction of suspected vascular aetiology. The test exploits the haemodynamic changes that occur in the cavernosal arteries during the transition from flaccidity to full erection, directly measuring blood flow parameters that reflect the functional integrity of the penile arterial and venous systems. Unlike questionnaire-based assessments or laboratory hormonal panels, PDDU provides objective, quantitative haemodynamic data that classifies the underlying pathophysiology of ED — distinguishing arteriogenic insufficiency, venogenic (corporal veno-occlusive) dysfunction, and mixed aetiology — with precision that directly guides treatment selection.
The three primary haemodynamic parameters measured are peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI). PSV reflects the maximum blood flow velocity in the cavernosal artery during the systolic phase and is the primary indicator of arterial inflow capacity: a PSV below 25 cm/s following adequate pharmacological erection induction indicates arterial insufficiency (arteriogenic ED). EDV reflects residual forward flow at the end of the diastolic phase; during a full erection, cavernosal venous outflow is normally occluded by the veno-occlusive mechanism of the tunica albuginea compressing the emissary veins. An EDV above 5 cm/s at full pharmacological erection indicates abnormal venous outflow — corporal veno-occlusive dysfunction (venogenic ED). The resistive index, calculated as (PSV − EDV) / PSV, should be 0.8 or greater in normal erectile physiology; an RI below 0.8 in conjunction with elevated EDV confirms the venogenic diagnosis.
The Treatment Protocol
The patient is positioned supine on the examination table. Baseline duplex Doppler measurements are obtained in the flaccid state from both cavernosal arteries — recording vessel diameter, waveform morphology, and baseline flow velocities. A small-gauge needle (27–30 gauge) is used to administer an intracavernosal injection of prostaglandin E1 (alprostadil, typically 10–20 μg) into the lateral aspect of the penile shaft, inducing pharmacological erection by direct smooth muscle relaxation and cavernosal arterial dilation. Serial Doppler measurements are then performed at 5, 10, 15, and 20 minutes post-injection as the erection progresses through tumescence, full erection, and rigid erection phases. PSV, EDV, and RI are recorded at each interval bilaterally. The penile angle and straightness are visually assessed during full pharmacological erection to detect Peyronie's deformity or congenital curvature as a concurrent finding.
At the conclusion of the study, if the patient has achieved a full rigid erection, the erection is monitored for spontaneous detumescence — which typically occurs within 30 to 90 minutes as prostaglandin E1 is metabolised. In patients who remain fully erect beyond 60 minutes without signs of detumescence, intracavernosal phenylephrine (a sympathomimetic vasoconstrictor, 200–500 μg) is administered as a reversal agent to initiate detumescence and prevent priapism. All facilities performing PDDU must maintain phenylephrine as an on-site reversal agent and must have a documented priapism management protocol.
Who is a Candidate
Penile duplex Doppler ultrasound is indicated for all patients with organic erectile dysfunction who are considering advanced treatment — including Li-ESWT, acoustic wave therapy, PRP or PRF injection, microsurgical penile revascularisation, or prosthetic implantation. The diagnostic information provided by PDDU is particularly critical before initiating any angiogenic treatment (Li-ESWT, shockwave therapy, PRP/PRF), as the arteriogenic confirmation substantially improves patient selection and outcome prediction for these modalities. A patient with venogenic ED will not benefit from angiogenic therapy directed at improving arterial inflow — the veno-occlusive failure is a fundamentally different pathophysiology requiring different management. Without PDDU, this distinction cannot be made reliably.
PDDU is also appropriate as a baseline investigation in men with significant cardiovascular risk factors presenting with new-onset ED, where arteriogenic erectile dysfunction may be an early sentinel manifestation of systemic atherosclerotic disease warranting cardiovascular risk stratification. Men with suspected Peyronie's disease benefit from PDDU to assess concurrent vascular aetiology and to document the erect angle and deformity characteristics under pharmacological conditions that more reliably reproduce the functional erect state than self-reported estimates.
Expected Outcomes and Timeline
PDDU is a diagnostic investigation, not a treatment — the outcome is actionable clinical information rather than symptom improvement. Results are reviewed with the patient immediately following the study by the urologist. Arteriogenic findings (PSV below 25 cm/s bilaterally) direct the patient toward angiogenic therapies — Li-ESWT, acoustic wave therapy, PRP/PRF injection — or, in appropriate younger patients with focal vascular occlusion, microsurgical penile revascularisation evaluation. Venogenic findings (EDV above 5 cm/s, RI below 0.8) indicate corporal veno-occlusive dysfunction, directing management toward different strategies including pharmacological optimisation, vacuum erection device use, or in selected cases surgical venous ligation evaluation. Normal arterial flow parameters in a symptomatic patient redirect the diagnostic workup toward psychogenic, neurogenic, or hormonal aetiologies.
The clinical value of PDDU extends beyond diagnosis into treatment optimisation and cost efficiency. Confirming that a patient has arteriogenic ED before committing to a $3,000–$6,000 Li-ESWT course maximises the probability of treatment success and avoids directing resources toward a modality that will not address the patient's actual pathophysiology. PDDU is consistently the most cost-effective single investigation in the andrological workup of organic ED.
Safety Profile and Risks
PDDU is a minimally invasive diagnostic procedure with a well-characterised safety profile. The primary risk is priapism — a pharmacologically induced erection persisting beyond 4 hours — occurring in approximately 1 to 3% of cases. Priapism is a medical urgency requiring prompt treatment with intracavernosal phenylephrine; all facilities performing PDDU must have phenylephrine immediately available and staff trained in its administration. Bruising or haematoma at the intracavernosal injection site is uncommon with proper needle technique and application of brief post-injection pressure. Mild transient discomfort at the injection site is reported by a minority of patients.
Cost and Accessibility
At $500 to $1,500, penile duplex Doppler ultrasound is a single diagnostic session priced well below the cost of empirically initiated treatment courses. The investment in PDDU before committing to a $3,000–$6,000 regenerative treatment protocol is justified by the clinical guidance it provides — confirming that the patient's ED aetiology is amenable to the proposed therapy, and identifying patients for whom that therapy is unlikely to be effective. Some insurance plans provide partial coverage for PDDU when performed as part of an ED workup with appropriate diagnostic coding; coverage varies substantially by plan.
Selecting a Qualified Provider
Penile duplex Doppler ultrasound requires a urologist with specific training in both intracavernosal injection technique and penile Doppler interpretation — this is not a general radiology study. The interpreting physician must understand the pharmacological erection stages, the normal Doppler waveform morphology at each stage, and the diagnostic thresholds for arteriogenic versus venogenic classification. ABU board-certified urologists with dedicated sexual medicine or andrology training, and active SMSNA membership, represent the appropriate provider profile. Patients should confirm that the facility performing the study has phenylephrine available and a documented priapism management protocol before consenting to the procedure.